On February 4, 2022 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences (Press release, Innate Pharma, FEB 4, 2022, View Source [SID1234607755]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 2022 Virtual Immuno-Oncology Summit
Event Date: February 16, 2022
SVB Leerink Virtual 11th Annual Global Healthcare Conference
Event Date: February 16, 2022

On February 4, 2022 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) reported that it has initiated a Phase Ib/II study in China of HMPL-453, an investigational novel selective inhibitor targeting fibroblast growth factor receptors ("FGFR") 1/2/3, in combination with chemotherapy or the anti-PD-1 therapy, toripalimab. The first patient received their first dose on January 22, 2022 (Press release, Hutchison China MediTech, FEB 4, 2022, View Source [SID1234607754]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical trial is a multi-center, two-stage, open-label study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy profile of HMPL-453 combination therapy in patients with specific advanced or metastatic solid tumors.

The first stage of the study is a dose escalation phase to determine the dose limiting toxicity (DLT) and recommended Phase II dose ("RP2D") of HMPL-453 in combination with chemotherapy (gemcitabine and cisplatin) or toripalimab. The second stage of the study is a dose expansion phase in solid tumor patients with either gastric cancer, intrahepatic cholangiocarcinoma, or urothelial carcinoma, harboring specific FGFR gene alterations. Each solid tumor cohort will be treated with a specific combination of HMPL‑453 and a chemotherapy or anti-PD-1 therapy to further evaluate the preliminary efficacy, safety and tolerability at the RP2D.

A Phase II study of HMPL-453 monotherapy is also underway in patients with advanced intrahepatic cholangiocarcinoma (IHCC) in China (clinicaltrials.gov identifier NCT04353375).

About HMPL‑453
HMPL‑453 is a novel, highly selective and potent inhibitor targeting FGFR 1, 2 and 3. Aberrant FGFR signaling has been found to be a driving force in tumor growth (through tissue growth and repair), promotion of angiogenesis and resistance to anti-tumor therapies. Abnormal FGFR gene alterations are believed to be the drivers of tumor cell proliferation in several solid tumor settings.

HUTCHMED currently retain all rights to HMPL-453 worldwide.

On February 4, 2022 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming virtual SVB Leerink 11th Annual Global Healthcare Conference (Press release, ImmunoGen, FEB 4, 2022, View Source [SID1234607753]). The presentation is scheduled for February 18, 2022 at 10:00am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be accessible through the "Investors and Media" section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.

On February 4, 2022 Privo Technologies, Inc. ("Privo"), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be "Tough on cancer, Easy on patients", reported that it will give a virtual company presentation and participate in one-on-one investor meetings at the 2022 BIO CEO & Investor Conference from February 14-17 (Press release, Privo Technologies, FEB 4, 2022, View Source;utm_medium=rss&utm_campaign=privo-technologies-inc-to-present-at-the-24th-annual-bio-ceo-investor-conference [SID1234607752]). Those looking to meet with Privo can schedule a meeting through the BIO One-on-One Partnering portal.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will focus on an introduction of the PRV platform technology’s lead assets (PRV111 and PRV211) and their respective upcoming clinical trial designs in oral cavity cancer (carcinoma and situ) and a basket study for all solid tumors. The localized targeted delivery of our nanoparticles allows the PRV platform to deliver high doses of potent chemotherapeutics while avoiding systemic side effects. This makes the platform particularly well suited for its lead indication, oral cavity cancer (OCC), which is a rare and disfiguring disease resulting in a poor quality of life due to the having no alternative treatment method to surgery. OCC is also known to acquire chemo resistance, which our efficacious nanoparticles mitigate. Privo is excited to showcase the potential of the PRV platform, a discovery that can prevent cancer from being a life changing event.

The Company’s presentation will be available on demand on the BIO CEO & Investor Conference website until March 20, 2022.

On February 4, 2022 Imago BioSciences, Inc. ("Imago") (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), reported that Hugh Y. Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on Thursday, February 10, 2022 at 10:30 a.m. PT / 1:30 p.m. ET (Press release, Imago BioSciences, FEB 4, 2022, View Source [SID1234607751]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.imagobio.com. The webcast replay will be available after the conclusion of the fireside chat for approximately 90 days.